BioLineRx Ltd. develops oncology and rare-disease therapies, with recurring updates centered on GLIX1, APHEXDA (motixafortide), and motixafortide development in solid tumors.
Company news covers GLIX1 clinical development for glioblastoma and other solid tumors under its Hemispherian collaboration, intellectual-property developments tied to GLIX1, financial results, and corporate updates. APHEXDA is approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma and is commercialized by partners, while BioLineRx has retained motixafortide rights for solid-tumor programs including metastatic pancreatic cancer.
BioLineRx (BLRX)/b) and Hemispherian will present new GLIX1 preclinical data and its Phase 1/2a trial design at EANO 2026 in Rome.One abstract, selected for a mini-oral session on September 25, 2026, details GLIX1’s potent anti-tumor activity in orthotopic glioblastoma xenograft models, where oral dosing produced dose-dependent tumor growth inhibition and survival benefit at all tested doses, with brain exposure reaching 68–85% of plasma levels. A second e-poster describes the actively enrolling, open-label, multicenter Phase 1/2a trial (NCT07464925) of GLIX1, an oral TET2 activator, in up to 30 patients with recurrent or progressive WHO grade 3/4 glioma, using a BOIN design across up to 5 dose levels, with primary endpoints of safety, tolerability, and MTD/RP2D.
BioLineRx (NASDAQ/TASE: BLRX) reported unaudited Q2 2026 results and pipeline progress. Royalty revenues were $0.3 million, broadly flat year over year, mainly from APHEXDA sales of $1.6 million, generating $0.3 million in royalty income. Research and development expenses rose to $2.9 million and general and administrative expenses to $0.9 million, driving a net loss of $4.3 million versus $3.9 million in Q2 2025.
Cash, cash equivalents and short-term deposits totaled $13.1 million as of June 30, 2026, with cash runway guided into the first half of 2027. According to BioLineRx, a $3.75 million equity offering signed on August 27, 2026 is expected to close around August 31, 2026.
Clinically, the second of five planned cohorts is dosing in the Phase 1/2a GLIX1 glioblastoma study, with a third cohort expected to start in September, supported by new preclinical GBM and ovarian cancer data and multiple upcoming conference presentations.
BioLineRx (NASDAQ: BLRX) announced a definitive agreement to sell an aggregate of 1,348,921 ADSs (or ADS equivalents) at $2.78 per ADS in a registered direct offering, plus accompanying warrants via a concurrent private placement to purchase up to 2,023,382 ADSs at an exercise price of $2.78.
The warrants will expire five years from issuance. Gross proceeds are expected to be $3.75 million before fees and expenses, with closing anticipated on or about August 31, 2026, subject to customary conditions. BioLineRx intends to use net proceeds for research and development, working capital and general corporate purposes.
In connection with the offering, BioLineRx agreed to amend outstanding warrants held by the investor to purchase 277,273 ADSs, reducing the exercise price to $2.78 and extending the expiration to August 31, 2031.
BioLineRx (NASDAQ: BLRX) announced it will release unaudited financial results for the second quarter ended June 30, 2026, on Monday, August 31, 2026, before U.S. markets open. Management will host a conference call at 8:30 a.m. EDT, featuring remarks by CEO Philip Serlin.
Investors can join the call by dialing +1-888-407-2553 from the U.S. or +972-3-918-0685 internationally. A live webcast and replay will be available via the event page on the company’s website. A dial-in replay will be accessible until September 1, 2026, at +1-888-295-2634 (U.S.) or +972-3-925-5904 (international).
BioLineRx (NASDAQ/TASE: BLRX) and Hemispherian announced acceptance of an e-Poster at ESMO 2026 presenting pre-clinical data showing strong synergy between GLIX1, a TET2-activating small molecule, and PARP inhibitors in HR-proficient ovarian cancer cell lines. The presentation will be held October 23–27, 2026, in Madrid.
BioLineRx (NASDAQ: BLRX) and Hemispherian reported new preclinical data in a patient-derived ovarian cancer xenograft model showing strong synergy between GLIX1 and the PARP inhibitor olaparib.
The low-dose GLIX1/olaparib combination achieved substantially better efficacy than control and monotherapies, with tumor reduction comparable to cisplatin. The companies plan to add an ovarian cancer arm to their ongoing Phase 1/2a study.
BioLineRx (NASDAQ: BLRX) reported unaudited Q1 2026 results and key oncology updates. Revenue was $0.5 million, mainly APHEXDA royalties, with APHEXDA Q1 sales of $2.7 million. Net loss was $2.6 million versus prior-year net income of $5.1 million, and cash/bank deposits totaled $17.4 million, supporting cash runway into H1 2027.
The first patient was dosed in the Phase 1/2a GLIX1 glioblastoma trial, with additional centers participating, and new preclinical GBM data showed potent anti-tumor effects, including in temozolomide-resistant models. Enrollment continues in the motixafortide Phase 2b mPDAC trial.
BioLineRx (NASDAQ: BLRX) and Hemispherian announced two ASCO 2026 abstracts on GLIX1, a first-in-class oral small molecule that restores TET2 activity and targets the DNA damage response.
Preclinical data show brain-penetrant antitumor activity in glioblastoma models, favorable animal safety, and synergistic cytotoxicity when combined with multiple PARP inhibitors. A first-in-human Phase 1/2a GBM trial (NCT07464925) is enrolling.
BioLineRx (NASDAQ: BLRX) will report unaudited Q1 2026 results on May 27, 2026, before U.S. markets open. Management will host a conference call at 8:30 a.m. EDT with CEO Philip Serlin, accessible via phone, live webcast, and replay.
BioLineRx (NASDAQ: BLRX) and Hemispherian reported new preclinical data on GLIX1 in glioblastoma (GBM). Orally administered GLIX1 showed dose-dependent anti-tumor activity in three orthotopic cell-derived xenograft models, with tumor growth inhibition and survival benefit across all doses.
In a new subcutaneous temozolomide (TMZ)-resistant patient-derived xenograft model, GLIX1 produced a robust anti-tumor effect while TMZ showed no effect, supporting the ongoing Phase 1/2a trial in recurrent and progressive GBM and other high-grade gliomas.